Empagliflozin

Details

Files

Generic Name:

Empagliflozin

Project Status:

Complete

Therapeutic Area:

Diabetes mellitus, type 2 with high cardiovascular risk

Manufacturer:

Boehringer Ingelheim (Canada) Ltd.

Call for patient/clinician input open:

March 30, 2016

Brand Name:

Jardiance

Project Line:

Reimbursement Review

Project Number:

SR0488-000

Call for patient/clinician input closed:

May 18, 2016

NOC Status at Filing:

Pre NOC

Performance Metric:

Achieved

Submission Type:

Initial

Indications:

Diabetes mellitus, type 2 with high cardiovascular risk

Recommendation Type:

Reimburse with clinical criteria and/or conditions

Final Recommendation:

October 26, 2016

Last Updated : March 30, 2016